Guardant Health Reports 48% Revenue Growth to $301.7 Million in Q1 2026

Guardant Health, Inc. reported significant financial results for the first quarter of 2026, with total revenue reaching $301.7 million, a 48% increase from $203.5 million in the same period last year. The growth was primarily driven by a substantial rise in oncology and screening revenues, which saw increases of 36% and 633%, respectively. Oncology revenue amounted to $205.0 million, while screening revenue surged to $41.6 million, reflecting the successful adoption of the Guardant Shield screening test following its FDA approval. Despite the revenue growth, the company recorded a net loss of $112.1 million, compared to a loss of $95.2 million in the prior year, resulting in a net loss per share of $0.85.

In terms of operational metrics, Guardant Health's test volume increased significantly, with approximately 86,000 oncology tests performed in the first quarter of 2026, up from about 59,000 in the same quarter of 2025. The company also reported a notable increase in its customer base, particularly in the biopharmaceutical sector, which contributed $53.0 million in revenue, a 17% increase year-over-year. The company’s total cash, cash equivalents, restricted cash, and marketable securities stood at approximately $1.2 billion as of March 31, 2026, providing a solid liquidity position to support ongoing operations and growth initiatives.

Guardant Health's operating expenses also rose, totaling $423.0 million for the quarter, up from $314.5 million in the previous year. The increase was largely attributed to higher sales and marketing expenses, which grew by 62% to $169.1 million, reflecting the company's investment in expanding its commercial infrastructure and marketing efforts. Research and development expenses increased modestly by 3% to $91.0 million, as the company continues to invest in product innovation and clinical studies.

Strategically, Guardant Health completed the acquisition of MetaSight Diagnostics Ltd. in December 2025, which is expected to enhance its product offerings and market position. The acquisition included an upfront cash payment of $59.0 million, with additional contingent consideration based on future performance. The company is also focused on expanding its international presence and has initiated several clinical studies to validate its products further, including the Shield multi-cancer detection test.

Looking ahead, Guardant Health anticipates continued revenue growth driven by increased test volumes and expanded payer coverage. The company is optimistic about its product pipeline and the potential for new market opportunities, particularly in the area of multi-cancer detection. However, it acknowledges the inherent risks associated with reimbursement variability and market conditions that could impact future performance.